[1]张克斌,杜 杰,彭 英.应用唑来膦酸预防实体瘤骨相关事件的疗效及生存研究[J].医学信息,2024,37(01):109-114.[doi:10.3969/j.issn.1006-1959.2024.01.018]
　ZHANG Ke-bin,DU Jie,PENG Ying.Study on the Efficacy and Survival of Zoledronic Acid in Preventing Skeletal Related Events in Solid Tumors[J].Journal of Medical Information,2024,37(01):109-114.[doi:10.3969/j.issn.1006-1959.2024.01.018]
点击复制

应用唑来膦酸预防实体瘤骨相关事件的疗效及生存研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年01期
页码:
109-114
栏目:
论著
出版日期:
2024-01-01

文章信息/Info

Title:
Study on the Efficacy and Survival of Zoledronic Acid in Preventing Skeletal Related Events in Solid Tumors
文章编号:
1006-1959（2024）01-0109-06
作者:
张克斌; 杜 杰; 彭 英
（水矿控股集团有限责任公司总医院肿瘤科，贵州 六盘水 553001）
Author(s):
ZHANG Ke-bin; DU Jie; PENG Ying
(Department of Oncology,General Hospital of Shuikuang Holding Group Co., Ltd.,Liupanshui 553001,Guizhou,China)
关键词:
实体瘤; 骨转移; 唑来膦酸; 骨相关事件; 无SREs生存期
Keywords:
Solid tumor; Bone metastasis; Zoledronic acid; Skeletal related events; Non-SREs time to progress
分类号:
R738.1
DOI:
10.3969/j.issn.1006-1959.2024.01.018
文献标志码:
A
摘要:
目的 探讨应用唑来膦酸（ZOL）前瞻性早期干预实体瘤骨转移、骨相关事件（SREs）的疗效，及对无骨转移、无SREs生存期（TTPS）、总生存期（OS）的影响。方法 选择2016年1月-2020年12月165例在本院治疗结束的患者，按照随机1∶2法分为观察组55例，为治疗结束即使用ZOL预防骨转移的患者，对照组110例为同期治疗结束的、不使用ZOL、定期随访的患者。观察两组骨转移及及SREs发生的比率及与生存的关系。结果 观察组骨转移3例（5.45%）、SREs2例（3.64%），分别低于对照组的26例（23.85%）、19例（17.43%），差异有统计学意义（P＜0.05）。两组OS和中位无进展生存期（MST）经Log-rank法比较无差异。观察组1~5年的TTPS和中位无骨转移生存期（MPST）分别为87%、62%、31%、13%、0和29.0个月（95%CI：25.371~32.629），与对照组的78%、55%、27%、2%、0和26.0个月（95%CI：21.717~30.283）比较，差异有统计学意义（?字2=4.155，P=0.040）。结论 尚未发生骨转移的实体瘤患者，在抗肿瘤专科治疗结束后，早期使用ZOL预防治疗，能使骨转移、SREs减少，TTPS延长。应用ZOL预防实体瘤骨转移、SREs有效，对无进展生存有益。
Abstract:
Objective To investigate the efficacy of zoledronic acid (ZOL) for a prospective early intervention in solid tumor bone metastasis, skeletal related events (SREs), and the effects on non-metastatic, non-SREs time to progress survival(TTPS), and overall survival(OS).Methods A total of 165 patients who were enrolled in our hospital from January 2016 to December 2020 were randomly divided into observation group (55 patients) and control group (110 patients) by 1:2 method. The patients in the observation group were treated with ZOL to prevent bone metastasis at the end of treatment, while the patients in the control group were treated without ZOL and followed up regularly at the end of the same period. The incidence of bone metastasis and SREs in the two groups and their relationship with survival were observed.Results There were 3 cases (5.45%) of bone metastasis and 2 cases (3.64%) of SREs in the observation group, which were lower than 26 cases (23.85%) and 19 cases (17.43%) in the control group, the differences were statistically significant (P<0.05). There was no difference in OS and median survival time (MST) between the two groups by Log-rank method. The 1-5-year TTPS and median progress survival tim(MPST) were 87%, 62%, 31%, 13%, 0 and 29.0 months (95%CI: 25.371-32.629) in the observation group, and 78%, 55%, 27%, 2%, 0 and 26.0 months (95%CI: 21.717-30.283) in the control group, the difference was statistically significant (?字2=4.155, P=0.040).Conclusion For patients with solid tumors that have not yet developed bone metastases, early use of ZOL prophylaxis after the end of anti-tumor specialist treatment can reduce the incidence of bone metastases and SREs, and prolong TTPS. Therefore, the application of ZOL to prevent solid tumor bone metastasis and SREs is effective and beneficial to progression-free survival.

参考文献/References:

[1]曹毛毛,陈万青.GLOBOCAN2020全球癌症统计数据解读[J].中国医学前沿杂志(电子版),2021,13(3):63-69.[2]夏晨波,沈国华,钱万锋.骨转移瘤的多学科诊疗模式探讨[J].浙江临床医学,2020,22(9):1379-1381.[3]张克斌,杜杰,彭英.早期应用唑来膦酸干预实体瘤骨相关事件对血清钙等生化指标的影响[J].山东第一医科大学(山东省医学科学院)学报,2022,43(6):446-449.[4]北京医学奖励基金会肺癌青年专家委员会,中国胸外科肺癌联盟.肺癌骨转移诊疗专家共识(2019版)[J].中国肺癌杂志,2019,22(4):187-207.[5]裴艳志,聂美楠,姜腾蛟,等.Ⅰ期非小细胞肺癌SLC及其受体CCR7的表达与淋巴结微转移关系[J].黑龙江医药科学,2020,43(6):1-3.[6]Bonetto R,Tallet A,Melot A,et al.The management of bone metastasis[J].Bull Cancer,2017,104(6):585-592.[7]Mu LL,Ke F,Guo XL,et al.Neoplasms in the bone marrow niches: disturbance of the microecosystem[J].Int J Hematol,2017,105(5):558-565.[8]Zhuang XQ,Zhang H,Li XY,et al.Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1[J].Nat Cell Biol,2017,19(10):1274-1285.[9]Grudowska A,Czaplińska D,Polom W,et al.Tetraspanin CD151 mediates communication between PC3 prostate cancer cells and osteoblasts[J].Acta Biochim Pol,2017,64(1):135-141.[10]Wang H,Tian L,Liu J,et al.The osteogenic Niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability[J].Cancer Cell,2018,34(5):823-839.e7.[11]Esposito M,Guise T,Kang YB.The biology of bone metastasis[J].Cold Spring Harb Perspect Med,2018,8(6): a031252.[12]Creamers S,Drake MT,Ebetino FH,et al.Pharmacology of bisphosphonates[J].Br J Clin Pharmacol,2019,85(6):1052-1062.[13]Huang XL,Huang LY,Cheng YT,et al.Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NFκB and JNK signalling pathways[J].Int J Mol Med,2019,44(2):582-592.[14]Li Y,Du Y,Sun T,et al.PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model[J].BMC Cancer,2018,18(1):669.[15]Kim BS,Yang SS,Kim CS,et al.Zoledronate suppresses VEGF-induced capillary tube formation and inhibits expression of interferon-induced transmembrane protein-1 in human umbilical vein endothelial cells[J].Int J Mol Med,2018,41(5):2879-2884.[16]Hortobagyi GN,Van Poznak C,Harker WG,et al.Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone:The optimize-2 randomized clinical trial[J].JAMA Oncol,2017,3(7):906-912.[17]Maurizi A,Rucci N.The Osteoclast in Bone Metastasis: Player and Target[J].Cancers (Basel),2018,10(218):1-18.[18]Stopeck AT,Lipton A,Body JJ,et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized，double-blind study[J].J Clin Oncol,2010,28(35):5132-5139.[19]Cristino J,Finek J,Jandova P,et al.Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic[J].J Med Econ,2017,20(8):799-812.[20]Coleman R,Cameron D,Dodwell D,et al.Adjuvant zoledronic acid in patients with early breast cancer:final efficacy analysis of the AZURE(BIG 01/04) randomised open-label phase 3 trial[J].Lancet Oncol,2014,15(9):997-1006.[21]徐丹,冷冰.唑来膦酸预防高危乳腺癌患者骨转移的效果观察[J].中国地方病防治杂志,2019,34(4):442-443.[22]焦咪.唑来膦酸对ⅢB/IV期肺癌患者骨转移预防作用的多中心、开放、随机对照研究[D].西安:第四军医大学,2017.

相似文献/References:

[1]廖 祺,黄 一,徐 雪.前列腺癌骨转移的疼痛管理[J].医学信息,2018,31(06):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
　LIAO Qi,HUANG Yi,XU Xue.Pain Management of Bone Metastasis in Prostate Cancer[J].Journal of Medical Information,2018,31(01):51.[doi:10.3969/j.issn.1006-1959.2018.06.017]
[2]李 科.骨形态发生蛋白4与乳腺癌骨转移的相关性研究[J].医学信息,2018,31(13):17.[doi:10.3969/j.issn.1006-1959.2018.13.005]
　LI Ke.Relationship between Bone Morphogenetic Protein 4 and Bone Metastasis in Breast Cancer[J].Journal of Medical Information,2018,31(01):17.[doi:10.3969/j.issn.1006-1959.2018.13.005]
[3]缪继东.盐酸吗啡缓释片联合低剂量阿米替林治疗中重度癌性骨痛的疗效观察[J].医学信息,2018,31(21):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]
　MIAO Ji-dong.Effects of Morphine Hydrochloride Sustained-release Tablets Combined with Low Dose Amitriptyline in the Treatment of Moderate and Severe Cancer Bone Pain[J].Journal of Medical Information,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]
[4]卜易莹,韩东兴,刘邦令,等.血清miR-145表达与乳腺癌患者的相关性分析[J].医学信息,2019,32(07):5.[doi:10.3969/j.issn.1006-1959.2019.07.002]
　BU Yi-ying,HAN Dong-xing,LIU Bang-ling,et al.Correlation Analysis between Serum miR-145 Expression and Breast Cancer Patients[J].Journal of Medical Information,2019,32(01):5.[doi:10.3969/j.issn.1006-1959.2019.07.002]
[5]李 博.唑来膦酸联合放疗治疗恶性肿瘤骨转移患者的效果[J].医学信息,2020,33(09):138.[doi:10.3969/j.issn.1006-1959.2020.09.044]
　YU Shou-jie,JIA Qian.The Effect of Zoledronic Acid Combined with Radiotherapy in Patients with Bone Metastases from Malignant TumorsLI Bo[J].Journal of Medical Information,2020,33(01):138.[doi:10.3969/j.issn.1006-1959.2020.09.044]
[6]李垄英,王启平,黄 慧.唑来膦酸、化疗联合多维度协同管理治疗非小细胞肺癌骨转移的疗效及对患者疼痛程度和生活质量的影响[J].医学信息,2022,35(21):98.[doi:10.3969/j.issn.1006-1959.2022.21.023]
　LI Long-ying,WANG Qi-ping,HUANG Hui.Efficacy of Zoledronic Acid and Chemotherapy Combined with Multidimensional Collaborative Management in the Treatment of Bone Metastasis of Non-small Cell Lung Cancer and its Effect on Pain Degree and Quality of Life[J].Journal of Medical Information,2022,35(01):98.[doi:10.3969/j.issn.1006-1959.2022.21.023]
[7]孔德伟,吴 铭,张 岩.肺腺癌骨转移肿瘤标记物的研究进展[J].医学信息,2022,35(23):171.[doi:10.3969/j.issn.1006-1959.2022.23.038]
　KONG De-wei,WU Ming,ZHANG Yan.Research Progress on Tumor Markers of Bone Metastasis in Lung Adenocarcinoma[J].Journal of Medical Information,2022,35(01):171.[doi:10.3969/j.issn.1006-1959.2022.23.038]
[8]王永祥,赵兴华,许长宝,等.初诊前列腺癌骨转移的危险因素分析及预测模型建立[J].医学信息,2023,36(11):16.[doi:10.3969/j.issn.1006-1959.2023.11.003]
　WANG Yong-xiang,ZHAO Xing-hua,XU Chang-bao,et al.Risk Factors Analysis and Prediction Model Establishment of Bone Metastasis in Newly Diagnosed Prostate Cancer[J].Journal of Medical Information,2023,36(01):16.[doi:10.3969/j.issn.1006-1959.2023.11.003]

更新日期/Last Update: 1900-01-01